Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00939848 2014-10-27

ABC-03

Phase 2/3 Completed

124 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00245063 2014-10-02

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00309946 2014-07-31

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Phase 2 Completed

51 enrolled 5 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00621725 2014-07-15

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Phase 1 Completed

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00494221 2014-03-27

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

Phase 1/2 Completed

172 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase 1 Completed

57 enrolled

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01229930 2013-08-26

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

130 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00305656 2013-08-22

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2 Completed

31 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00310089 2013-06-20

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Phase NA Completed

33 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00238394 2013-06-05

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

44 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00321724 2013-01-15

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

35 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

BAROCCO

OCTOVA

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

CONCERTO

MOLTO

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

AZD2171 to Treat Prostate Cancer

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

HORIZON III

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

HORIZON II

REGAL

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

ABC-03

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia